Cardiol Free Cash Flow Per Share vs Ev To Sales Analysis

CRDL Stock

CAD 1.93 0.10 4.93%

Cardiol Therapeutics financial indicator trend analysis is way more than just evaluating Cardiol Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cardiol Therapeutics is a good investment. Please check the relationship between Cardiol Therapeutics Free Cash Flow Per Share and its Ev To Sales accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Free Cash Flow Per Share vs Ev To Sales

Free Cash Flow Per Share vs Ev To Sales Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cardiol Therapeutics Free Cash Flow Per Share account and Ev To Sales. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Cardiol Therapeutics' Free Cash Flow Per Share and Ev To Sales is -0.32. Overlapping area represents the amount of variation of Free Cash Flow Per Share that can explain the historical movement of Ev To Sales in the same time period over historical financial statements of Cardiol Therapeutics Class, assuming nothing else is changed. The correlation between historical values of Cardiol Therapeutics' Free Cash Flow Per Share and Ev To Sales is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow Per Share of Cardiol Therapeutics Class are associated (or correlated) with its Ev To Sales. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ev To Sales has no effect on the direction of Free Cash Flow Per Share i.e., Cardiol Therapeutics' Free Cash Flow Per Share and Ev To Sales go up and down completely randomly.

Correlation Coefficient

-0.32

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Free Cash Flow Per Share

The amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Most indicators from Cardiol Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cardiol Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

As of the 13th of December 2024, Selling General Administrative is likely to drop to about 14.6 M. In addition to that, Issuance Of Capital Stock is likely to drop to about 39.4 M

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	220.4K	219.9K	248.4K	190.7K
Interest Income	6.9M	1.2M	2.2M	2.9M

Depreciation And Amortization Interest Income

Cardiol Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Long Term Debt Total	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Cash And Equivalents
Total Assets		-0.67	0.95	0.96	1.0	0.96	0.55	-1.0	-0.76	0.76	1.0	-0.29	-0.74	1.0	0.49	0.78	0.73	-0.7	-0.72	0.5	0.81	0.96	0.96	0.79	1.0	0.92
Short Long Term Debt Total	-0.67		-0.77	-0.71	-0.66	-0.59	-0.49	0.71	0.65	-0.62	-0.71	0.18	0.65	-0.71	-0.19	-0.46	-0.75	0.83	0.96	-0.31	-0.64	-0.71	-0.59	-0.67	-0.67	-0.66
Other Current Liab	0.95	-0.77		0.99	0.93	0.97	0.57	-0.96	-0.86	0.83	0.96	-0.38	-0.78	0.96	0.36	0.79	0.9	-0.85	-0.79	0.4	0.91	0.99	0.97	0.87	0.95	0.94
Total Current Liabilities	0.96	-0.71	0.99		0.95	0.98	0.54	-0.97	-0.86	0.85	0.97	-0.41	-0.77	0.97	0.39	0.81	0.87	-0.81	-0.74	0.4	0.9	1.0	0.98	0.86	0.97	0.96
Total Stockholder Equity	1.0	-0.66	0.93	0.95		0.94	0.55	-0.99	-0.74	0.74	0.99	-0.26	-0.73	0.99	0.51	0.77	0.7	-0.68	-0.72	0.52	0.79	0.95	0.94	0.77	1.0	0.9
Net Tangible Assets	0.96	-0.59	0.97	0.98	0.94		0.57	-0.95	-0.84	0.82	0.95	-0.36	-0.77	0.95	0.46	0.84	0.83	-0.76	-0.65	0.47	0.9	0.98	1.0	0.86	0.96	0.95
Property Plant And Equipment Net	0.55	-0.49	0.57	0.54	0.55	0.57		-0.51	-0.66	0.45	0.51	0.42	-0.94	0.51	0.76	0.83	0.54	-0.71	-0.69	0.82	0.74	0.54	0.57	0.85	0.55	0.55
Net Debt	-1.0	0.71	-0.96	-0.97	-0.99	-0.95	-0.51		0.77	-0.77	-1.0	0.34	0.72	-1.0	-0.42	-0.75	-0.75	0.73	0.75	-0.44	-0.81	-0.97	-0.95	-0.78	-1.0	-0.93
Retained Earnings	-0.76	0.65	-0.86	-0.86	-0.74	-0.84	-0.66	0.77		-0.95	-0.76	0.39	0.86	-0.76	-0.46	-0.83	-0.91	0.93	0.69	-0.41	-0.95	-0.86	-0.84	-0.89	-0.76	-0.92
Accounts Payable	0.76	-0.62	0.83	0.85	0.74	0.82	0.45	-0.77	-0.95		0.76	-0.59	-0.7	0.76	0.41	0.71	0.89	-0.84	-0.61	0.31	0.86	0.85	0.82	0.77	0.76	0.9
Cash	1.0	-0.71	0.96	0.97	0.99	0.95	0.51	-1.0	-0.76	0.76		-0.33	-0.72	1.0	0.42	0.75	0.75	-0.72	-0.74	0.44	0.81	0.97	0.95	0.78	1.0	0.92
Non Current Assets Total	-0.29	0.18	-0.38	-0.41	-0.26	-0.36	0.42	0.34	0.39	-0.59	-0.33		-0.11	-0.33	0.38	-0.03	-0.45	0.24	-0.01	0.52	-0.26	-0.42	-0.36	-0.05	-0.29	-0.46
Non Currrent Assets Other	-0.74	0.65	-0.78	-0.77	-0.73	-0.77	-0.94	0.72	0.86	-0.7	-0.72	-0.11		-0.72	-0.7	-0.92	-0.75	0.87	0.79	-0.72	-0.91	-0.76	-0.77	-0.95	-0.74	-0.78
Cash And Short Term Investments	1.0	-0.71	0.96	0.97	0.99	0.95	0.51	-1.0	-0.76	0.76	1.0	-0.33	-0.72		0.42	0.75	0.75	-0.72	-0.74	0.44	0.81	0.97	0.95	0.78	1.0	0.92
Net Receivables	0.49	-0.19	0.36	0.39	0.51	0.46	0.76	-0.42	-0.46	0.41	0.42	0.38	-0.7	0.42		0.66	0.31	-0.38	-0.39	0.93	0.52	0.39	0.46	0.62	0.49	0.41
Common Stock Total Equity	0.78	-0.46	0.79	0.81	0.77	0.84	0.83	-0.75	-0.83	0.71	0.75	-0.03	-0.92	0.75	0.66		0.73	-0.73	-0.63	0.59	0.93	0.81	0.83	0.91	0.78	0.78
Common Stock Shares Outstanding	0.73	-0.75	0.9	0.87	0.7	0.83	0.54	-0.75	-0.91	0.89	0.75	-0.45	-0.75	0.75	0.31	0.73		-0.92	-0.74	0.3	0.93	0.87	0.83	0.89	0.73	0.84
Long Term Debt Total	-0.7	0.83	-0.85	-0.81	-0.68	-0.76	-0.71	0.73	0.93	-0.84	-0.72	0.24	0.87	-0.72	-0.38	-0.73	-0.92		0.85	-0.44	-0.9	-0.81	-0.76	-0.89	-0.7	-0.85
Non Current Liabilities Total	-0.72	0.96	-0.79	-0.74	-0.72	-0.65	-0.69	0.75	0.69	-0.61	-0.74	-0.01	0.79	-0.74	-0.39	-0.63	-0.74	0.85		-0.49	-0.72	-0.73	-0.64	-0.78	-0.72	-0.68
Other Current Assets	0.5	-0.31	0.4	0.4	0.52	0.47	0.82	-0.44	-0.41	0.31	0.44	0.52	-0.72	0.44	0.93	0.59	0.3	-0.44	-0.49		0.49	0.39	0.46	0.65	0.5	0.41
Other Stockholder Equity	0.81	-0.64	0.91	0.9	0.79	0.9	0.74	-0.81	-0.95	0.86	0.81	-0.26	-0.91	0.81	0.52	0.93	0.93	-0.9	-0.72	0.49		0.9	0.9	0.97	0.81	0.89
Total Liab	0.96	-0.71	0.99	1.0	0.95	0.98	0.54	-0.97	-0.86	0.85	0.97	-0.42	-0.76	0.97	0.39	0.81	0.87	-0.81	-0.73	0.39	0.9		0.98	0.85	0.97	0.96
Net Invested Capital	0.96	-0.59	0.97	0.98	0.94	1.0	0.57	-0.95	-0.84	0.82	0.95	-0.36	-0.77	0.95	0.46	0.83	0.83	-0.76	-0.64	0.46	0.9	0.98		0.86	0.96	0.95
Property Plant And Equipment Gross	0.79	-0.67	0.87	0.86	0.77	0.86	0.85	-0.78	-0.89	0.77	0.78	-0.05	-0.95	0.78	0.62	0.91	0.89	-0.89	-0.78	0.65	0.97	0.85	0.86		0.79	0.83
Total Current Assets	1.0	-0.67	0.95	0.97	1.0	0.96	0.55	-1.0	-0.76	0.76	1.0	-0.29	-0.74	1.0	0.49	0.78	0.73	-0.7	-0.72	0.5	0.81	0.97	0.96	0.79		0.92
Cash And Equivalents	0.92	-0.66	0.94	0.96	0.9	0.95	0.55	-0.93	-0.92	0.9	0.92	-0.46	-0.78	0.92	0.41	0.78	0.84	-0.85	-0.68	0.41	0.89	0.96	0.95	0.83	0.92

Click cells to compare fundamentals

Cardiol Therapeutics Account Relationship Matchups

Cardiol Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	15.5M	15.9M	87.9M	62.0M	36.7M	38.6M
Short Long Term Debt Total	190.8K	156.6K	117.6K	72.9K	174.3K	133.9K
Other Current Liab	640.1K	2.5M	11.5M	9.8M	8.3M	5.1M
Total Current Liabilities	690.5K	2.5M	11.6M	9.8M	8.3M	5.5M
Total Stockholder Equity	14.7M	13.3M	76.2M	52.2M	28.2M	33.0M
Net Tangible Assets	14.1M	12.8M	75.9M	51.9M	59.7M	32.7M
Property Plant And Equipment Net	584.0K	479.6K	356.5K	295.7K	337.1K	329.6K
Net Debt	(6.8M)	(13.9M)	(83.8M)	(59.4M)	(34.7M)	(36.4M)
Retained Earnings	(31.2M)	(51.9M)	(83.5M)	(114.4M)	(142.6M)	(135.4M)
Accounts Payable	561.3K	1.8K	4.2M	8.3M	7.6M	8.0M
Cash	7.0M	14.0M	83.9M	59.5M	34.9M	34.3M
Non Current Assets Total	1.1M	943.2K	735.7K	590.5K	547.4K	610.6K
Cash And Short Term Investments	7.0M	14.0M	83.9M	59.5M	34.9M	34.3M
Net Receivables	927.9K	219.9K	407.1K	480.2K	279.9K	452.2K
Common Stock Shares Outstanding	25.8M	29.9M	43.2M	62.5M	64.5M	41.5M
Long Term Debt Total	140.3K	104.7K	72.9K	22.4K	20.2K	19.2K
Liabilities And Stockholders Equity	15.5M	15.9M	87.9M	62.0M	36.7M	38.6M
Non Current Liabilities Total	140.3K	104.7K	72.9K	22.4K	158.5K	109.5K
Other Current Assets	5.4M	686.9K	2.8M	1.5M	941.4K	1.9M
Other Stockholder Equity	6.5M	8.8M	12.7M	15.6M	18.8M	10.3M
Total Liab	830.8K	2.6M	11.6M	9.8M	8.5M	5.7M
Net Invested Capital	14.7M	13.3M	76.2M	52.2M	60.0M	33.4M
Property Plant And Equipment Gross	584.0K	479.6K	713.9K	788.6K	906.9K	478.6K
Total Current Assets	14.4M	14.9M	87.1M	61.4M	36.2M	37.8M
Accumulated Other Comprehensive Income	(76.3K)	4.5M	4.2M	3.5M	4.0M	2.4M
Cash And Equivalents	7.0M	14.0M	83.9M	59.5M	68.4M	71.8M
Net Working Capital	13.7M	12.4M	75.6M	51.6M	59.4M	32.5M
Short Term Debt	50.5K	51.9K	44.7K	50.4K	15.8K	15.0K
Intangible Assets	548.1K	463.7K	379.2K	294.8K	210.4K	371.0K
Common Stock	39.4M	51.9M	142.9M	147.5M	148.5M	89.8M
Property Plant Equipment	584.0K	479.6K	356.5K	295.7K	340.1K	322.7K
Capital Surpluse	4.8M	8.8M	12.7M	15.6M	17.9M	9.5M
Capital Stock	39.4M	51.9M	142.9M	147.5M	169.7M	92.1M

Pair Trading with Cardiol Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cardiol Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cardiol Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Cardiol Stock

0.86	AEMC	Alaska Energy Metals	Pair Corr
0.77	CMC	Cielo Waste Solutions Earnings Call This Week	Pair Corr

Moving against Cardiol Stock

0.81	MATE	Blockmate Ventures	Pair Corr
0.75	LQWD	LQwD FinTech Corp	Pair Corr

The ability to find closely correlated positions to Cardiol Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cardiol Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cardiol Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cardiol Therapeutics Class to buy it.

The correlation of Cardiol Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cardiol Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cardiol Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Cardiol Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Cardiol Therapeutics is a strong investment it is important to analyze Cardiol Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cardiol Therapeutics' future performance. For an informed investment choice regarding Cardiol Stock, refer to the following important reports:

How To Invest In Cardiol

Details

Is Cardiol Stock a good investment?

Details

What is Cardiol Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.

Please note, there is a significant difference between Cardiol Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiol Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiol Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cardiol Free Cash Flow Per Share vs Ev To Sales Analysis

Free Cash Flow Per Share vs Ev To Sales

Free Cash Flow Per Share vs Ev To Sales Correlation Analysis

Correlation Coefficient

Free Cash Flow Per Share

Ev To Sales

Cardiol Therapeutics fundamental ratios Correlations

Cardiol Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cardiol Therapeutics fundamental ratios Accounts

Pair Trading with Cardiol Therapeutics

Moving together with Cardiol Stock

Moving against Cardiol Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Total Current Assets	+ 1.0	Total Stockholder Equity

Total Current Assets	- 1.0	Net Debt
Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 1.0	Total Assets
Net Debt	- 0.99	Total Stockholder Equity
Total Liab	- 0.97	Net Debt